2m 2m 2m 2m 2m 2m 2m
- $390.5MMarket Cap
- 70.43%1-Year Change
- BiotechnologyIndustry
FORTE BIOSCIENC (FBRX)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 60
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Over 18 pharmaceutical companies are developing targeted therapies for vitiligo, with promising pipeline drugs showing potential to transform treatment options beyond conventional approaches like corticosteroids and phototherapy.
08/14/2025, 1:00 PM • GlobeNewswire
Forte and Sequence Partner to Power Web3 Monetization Through Integrated Payment Infrastructure
Forte, through its subsidiary LemmaX, partnered with Sequence to integrate FortePay as a comprehensive payment infrastructure, enabling developers to process multi-chain payments with enhanced compliance and user experience across blockchain networks.
07/04/2025, 6:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Key Executives
- Paul A. Wagner
- Antony A. Riley
- Barbara K. Finck
- Christopher Roenfeldt
Current Ownership Distribution
- Institutions149.9M (77.78%)
- Mutual Funds39.1M (20.31%)
- Insiders3.7M (1.91%)
- Other0 (0.00%)